Interactive Transcript
0:00
All right. Hello and welcome to Noon conference hosted by MRI online.
0:05
In response to the changes happening around the world right now and the
0:08
shutting down of in person events, we have decided to provide free noon
0:10
conferences to all radiologists worldwide. Today we're joined by Dr. Lacey
0:14
McIntosh. She is an assistant professor of radiology at UMass Medical School
0:17
and specializes in cancer and molecular imaging. She currently serves as
0:20
the director of oncology imaging at UMass Memorial Healthcare. She is teaching
0:24
and working with residents. Just a reminder that we will have time at
0:26
the end of the session for a Q&A part of that and you
0:30
can feel free to use the Q&A feature to ask your questions.
0:33
We'll get to as many as we can before our time is up.
0:35
That being said, thanks for joining us today, Dr. McIntosh. I'll let you
0:38
take it from here. Wonderful. Thank you for having me.
0:42
This is a great program. I've myself logged into a couple of
0:46
the Noon conferences to learn from some of these wonderful colleagues of
0:50
ours. I'm coming to you guys today from Massachusetts, but
0:55
I see from the participant list it looks like we have people from
0:59
all over the world here, which is really
1:01
a cool way to get the radiology or people interested in radiology community
1:05
together. Thank you for having me. Today I'm gonna talk about pulmonary
1:12
nodule characterization, diagnosis and staging. Really focusing on the pulmonary
1:17
nodules that end up becoming lung cancer. The two modalities we're really
1:23
gonna be talking about are CT and PET CT. I think it's important
1:27
that if you are looking at pulmonary nodules, either from
1:32
a general radiologist standpoint or if you're a dedicated
1:37
cardiothoracic or thoracic imager, or if you're more on the nuclear medicine
1:42
side where you're reading PET CT, it's really important to integrate the
1:46
imaging to come up with the best interpretation. You really can't read either
1:51
of these in isolation and you have to synthesize all the information that
1:56
you have together. We're gonna look at using the two modalities together
2:01
to get the best guess of what's going on with these patients.
2:05
Disclosures, I work as a consultant for BioClinica, which does clinical
2:10
trial reads. And mostly for cancer drugs and novel tracers, but nothing
2:16
pertinent to this lecture. In terms of lung cancer imaging, we use CT
2:23
to really characterize size, morphology, look at local invasion of structures.
2:29
It's always helpful when you're evaluating pulmonary nodule if you have
2:32
multiple time points and you can assess the behavior over time.
2:35
Sometimes when you see a pulmonary nodule just on one study,
2:38
it's really hard to know, is this something that's been there forever and
2:41
it's unchanged or has this been slowly growing?
2:45
Is this something that wasn't there a week ago? Because that really changes
2:48
your differential. Behavior over time is a big one.
2:53
When you're using PET CT... Today I'm only speaking about 18 fluorodeoxyglucose
2:59
or FDG, which is basically a radioactive sugar molecule and is taken up
3:05
by any metabolizing cells. Obviously, we have normal tissues that are going
3:10
to have uptake like brain, sometimes myocardium, the GI tract.
3:15
We see it being excreted renally in the renal collecting system,
3:19
but we also see it with other things like infection, inflammation,
3:22
and cancers. While it's not specific for cancer, this is the primary tracer
3:27
right now that we use to look at the metabolic activity of certain
3:31
cancers. Depending on what your institution or your center does, the CT
3:39
portion can range from being a full contrast enhanced diagnostic CT to
3:46
really just a non contrast CT that's utilized for localization and has a
3:51
somewhat limited diagnostic value. I think that majority of cases,
4:00
these are being done with non contrast, so they're not a full diagnostic
4:05
value. The other issues are that we have a very large field of
4:08
view. The slices are often thick, five millimeters. And to avoid misregistration,
4:14
we usually take the CT with a tidal breathing technique. And so,
4:19
we don't ask the patient to take a breath and hold it.
4:22
We might take the CT portion as they're breathing or basically just ask
4:26
them to stop breathing. The reason for that is that we collect the
4:31
PET data over 20 to 30 to 40 minutes, and patient's obviously breathing
4:36
through all of that. If you have the patient take a deep breath
4:39
and do the CT portion, then you're gonna have a lot of misregistration.
4:42
And that's very important for pulmonary nodules, especially in the lower
4:46
lobes. PET CT provides functional information about the metabolic activity
4:51
of tissues. So, not only are you getting an idea of what your
4:55
nodule is doing, but sometimes more importantly, we're looking for evidence
4:59
of spread to the nodes regionally as well as distant metastatic disease.
5:06
As I mentioned, this isn't specific for cancer, but a positive PET doesn't
5:11
always equal cancer. There's false positives, infection, inflammation
5:16
being some of those. And then, a negative PET doesn't always equal no
5:21
cancer, so we can have false negatives as well. And one of the
5:25
areas that we really think about that are with slow growing lung cancers
5:30
and very small findings. Things that are larger are gonna be more FDG
5:34
avid. And the reason for that is they have more cells with GLUT1 transporters,
5:39
and so they're able to take up more tracer.
5:42
Small findings just don't have as many cells, and so
5:45
your accumulation is gonna be different. What you define as positive and
5:49
negative has to be taken into perspective about size of your finding.
5:55
One of the things that PET can be really useful for is
5:58
it can be helpful when your anatomic information is limited. If you have
6:03
an endobronchial lesion and you have post obstructive collapse, it can sometimes
6:07
be really hard to tell where your tumor is. And if you're trying
6:10
to figure out how to biopsy it or how suspicious it is,
6:13
PET can be really, really helpful. This is an example from the literature,
6:17
which is showing collapse of the right upper lobe. And you can actually
6:20
see this right upper lobe bronchus is basically cut off and it's filled
6:24
with something. Is it mucus and just post obstructive collapse from that,
6:28
or is it actually tumor? We see on the PET CT that this
6:32
is very FDG avid. It's right in the location we're expecting,
6:36
and so mucus is not gonna do this. This is a tumor with
6:39
post obstructive collapse. And so now we actually know the size of it,
6:42
which is important for T staging. We know the location, which is really
6:46
important for biopsy planning. It can give you a lot of information and
6:52
be very helpful when the anatomy is challenging.
6:55
Here's a case from our institution which is showing left lower lobe collapse.
© 2024 MRI Online. All Rights Reserved.